Get the Stockscreener App
4.05
1.46%
-0.06
After Hours:
4.05
Cingulate Inc stock is traded at $4.05, with a volume of 79,135.
It is down -1.46% in the last 24 hours and up +2.53% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.11
Open:
$4.15
24h Volume:
79,135
Relative Volume:
0.54
Market Cap:
$21.92M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1242
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
-0.98%
1M Performance:
+2.53%
6M Performance:
+6.58%
1Y Performance:
-16.32%
1-Day Range:
$3.962
$4.15
1-Week Range:
$3.91
$4.44
52-Week Range:
$3.02
$6.01
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.05 | 23.04M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
How Cingulate Inc. Equity Warrant stock trades before earningsWatch List & Daily Market Momentum Tracking - newser.com
How supply chain issues affect Cingulate Inc. stockOil Prices & Consistent Growth Equity Picks - newser.com
Will Cingulate Inc. stock remain a Wall Street favoriteJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Backtesting results for Cingulate Inc. Equity Warrant trading strategiesOil Prices & Consistent Growth Equity Picks - newser.com
Can Cingulate Inc. stock deliver consistent earnings growthTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
What institutional flow reveals about Cingulate Inc.Quarterly Growth Report & Capital Efficient Trading Techniques - newser.com
Is Cingulate Inc a good long term investmentREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Will Cingulate Inc. continue its uptrendPortfolio Update Summary & AI Driven Stock Price Forecasts - newser.com
Cingulate Inc. (NASDAQ:CING) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Is Cingulate Inc. stock entering bullish territoryCEO Change & Smart Money Movement Alerts - newser.com
What’s next for Cingulate Inc. stock priceWeekly Earnings Recap & Fast Entry Momentum Alerts - newser.com
Analyzing drawdowns of Cingulate Inc. Equity Warrant with statistical tools2025 Year in Review & Stock Timing and Entry Methods - newser.com
How Cingulate Inc. stock compares to industry benchmarksQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
Market reaction to Cingulate Inc.’s recent newsDividend Hike & Consistent Income Trade Ideas - newser.com
Is Cingulate Inc. a candidate for recovery playInsider Selling & Weekly Chart Analysis and Guides - newser.com
Will Cingulate Inc. bounce back from current supportMarket Weekly Review & Weekly High Return Forecasts - newser.com
Is Cingulate Inc. stock bottoming outJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Cingulate Inc. stock retracement – recovery analysisTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
What does recent volatility data suggest for Cingulate Inc.Trade Analysis Report & Verified Swing Trading Watchlist - newser.com
Using flow based indicators on Cingulate Inc.July 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Will Cingulate Inc. stock gain from government policiesJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Why Cingulate Inc. stock could be next big winner2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Understanding Cingulate Inc. Equity Warrant’s price movementQuarterly Profit Summary & Precise Buy Zone Identification - newser.com
Real time breakdown of Cingulate Inc. Equity Warrant stock performanceJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Tools to monitor Cingulate Inc. Equity Warrant recovery probability - newser.com
Is it too late to sell Cingulate Inc.2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
What drives Cingulate Inc Equity Warrant stock priceSupport Zone Identification & The Smart Money Is Buying These Picks - earlytimes.in
Torrent Pharmaceuticals Limited (500420) Hits 52 Week HighMomentum Trading Signals & Low Risk Wealth Plans - earlytimes.in
Can trapped investors hope for a rebound in Cingulate Inc.Insider Buying & Safe Capital Allocation Plans - newser.com
Using AI based signals to follow Cingulate Inc.Portfolio Value Report & Expert Verified Stock Movement Alerts - newser.com
Chart based exit strategy for Cingulate Inc. Equity WarrantWeekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):